Advertisement

Related Videos

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Opportunities to Optimize Cancer Policies Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Advertisement

Advertisement




Nov
15
Today In Oncology
Triplet Therapy With Abiraterone Improves OS Long-Term in Metastatic Castration-Sensitive Prostate Cancer
FDA Approves Durvalumab With Enfortumab Vedotin-ejfv for Muscle-Invasive Bladder Cancer
FDA Grants Accelerated Approval to Amivantamab and Hyaluronidase for Previously Treated HNSCC
American Cancer Society Updates Prostate Cancer Screening Guideline
Phase III VOLGA Trial Explores Outcomes in Muscle Invasive Bladder Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo